Literature DB >> 22394463

RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population.

Süleyman Bayram1.   

Abstract

AIM: The tumor suppressor gene Ras association domain family 1 isoform A (RASSF1A) regulates cell cycle regulation, apoptosis and microtubule stability and is inactivated by promoter hypermethylation at a high frequency in hepatocellular carcinoma (HCC). A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein.
METHODS: To determine the association of the RASSF1A Ala133Ser polymorphism with the risk of HCC development in a Turkish population, a hospital-based case-control study was designed consisting of 236 subjects with HCC and 236 cancer-free control subjects matched for age, gender, smoking and alcohol status. The genotype frequency of the RASSF1A Ala133Ser polymorphism was determined by using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.
RESULTS: Allele and genotype associations of RASSF1A Ala133Ser polymorphism with HCC susceptibility were observed in comparisons between the patient and control samples (P<0.001). Risk of HCC development in this Turkish population was significantly increased in carriers of the Ser133 variant allele of Ala133Ser polymorphism (Ala/Ser and Ser/Ser genotypes) when compared with homozygote Ala/Ala genotype (OR=5.47, 95% CI=3.63-8.25, P=0.001).
CONCLUSION: Because our results suggest for the first time that the Ser133 allele of RASSF1A Ala133Ser polymorphism may be a genetic susceptibility factor for HCC in the Turkish population, further independent studies are required to validate our findings in a larger series, as well as in patients of different ethnic origins. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22394463     DOI: 10.1016/j.gene.2012.02.040

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

1.  Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.

Authors:  Yong-Shuang Li; Qiang Xie; Da-Ye Yang; Yuan Zheng
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

2.  Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma.

Authors:  Nermin A Ali; Nadia M Hamdy; Abdullah A Gibriel; Hala O El Mesallamy
Journal:  Arch Virol       Date:  2021-04-01       Impact factor: 2.574

Review 3.  Clinical utility of RASSF1A methylation in human malignancies.

Authors:  A M Grawenda; E O'Neill
Journal:  Br J Cancer       Date:  2015-07-09       Impact factor: 7.640

4.  The Association of Ala133Ser Polymorphism and Methylation in Ras Association Domain Family 1A Gene With Unfavorable Prognosis of Hepatocellular Carcinoma.

Authors:  Ying Feng; Peng Li; Yifei Liu; Zhenyu Sha; Liang Feng; Fei Wang; Qinsheng Mao; Wanjiang Xue
Journal:  Hepat Mon       Date:  2015-10-28       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.